An international collaboration led by RIKEN researchers has discovered how unusual spherical structures form in the brains of ...

Figure 1: A new W-shaped structural model of E22G 40-residue beta-amyloid fibrils. RIKEN researchers have shown how the ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.

"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...

Dementia is a debilitating neurodegenerative disease that gradually diminishes life quality, leading to memory loss, ...

Some researchers seek to establish a single abnormal result on a set of biomarker-based tests as sufficient to diagnose the ...

IGC-AD1 significantly impacts both amyloid-beta plaques and tau pathology-two critical drivers in Alzheimer's ...

Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.

A new interdisciplinary study at the University of Delaware seeks to study AD by examining changes in the arteries and brain ...

Ann Lange was diagnosed with Alzheimer's in 2015, but with the help of clinical trials her disease has not progressed past ...